‘Pivotal year’ sees obesity business address its losses
A life sciences business specialising in weight loss has added significant bulk in what its chief executive has described as "a pivotal year".
Optibiotix focuses on fighting obesity, high blood cholesterol, and diabetes by developing microbial strains and compounds for use in ingredients and supplements.
Sales have more than doubled to £1.5m, compared against a 13-month financial year, with improvements in operating profitability in key divisions at the York-based business.
A large reduction in costs in its Probiotic and Fun... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
